S100A12, Human, mAb 203, biotinylated
The monoclonal antibody clone 203 recognizes S100 calcium-binding protein A12 (S100A12). The antibody does not cross-react with family members S100A7, S100A8 and S100A9 and S100A8/A9 heterodimers. S100A12, also known as calgranulin C, is a member of the S100 protein family. To date, the family consists of 22 members. S100 proteins are low molecular weight calcium binding proteins. The proteins consist of 2 calcium binding EF-hands located on the termini flanked by hydrophobic hinge regions. Calcium ions acts as a global second messenger involved in the regulation of many aspects of cell function. S100 proteins are involved in sensing and transforming calcium signals to downstream cellular responses. S100 proteins are located in the cytoplasm and/or nucleus of a wide range of cell types and involved in the regulation of cellular processes such as cell cycle progression and differentiation and inflammatory responses. Several S100 members have been found to act as cytokines in inflammation, particularly in autoimmune skin conditions such as psoriasis. S100A12 is involved in calcium-dependent signal transduction pathways and has regulatory effects on cytoskeletal components thereby modulating neutrophil activities. Studies have shown that S100A12 might have potential as a biomarker for arthritis since their levels correlate with disease activity and are able to predict relapse and response to anti-inflammatory therapy. Unfortunately, studying the biology of S100A12 and other calgranulins is challenging due to its tendency to form complex homodimer, heterodimer and heterotetramers structures.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA